Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/227766 
Erscheinungsjahr: 
2020
Schriftenreihe/Nr.: 
DIW Discussion Papers No. 1918
Verlag: 
Deutsches Institut für Wirtschaftsforschung (DIW), Berlin
Zusammenfassung: 
We investigate patterns in common ownership networks between firms that are active in the US pharmaceutical industry for the period 2004-2014. Our main findings are that "brand firms" - i.e. firms that have R&D capabilities and launch new drugs - exhibit relatively dense common ownership networks with each other that further increase significantly in density over time, whereas the network of "generic firms" - i.e. firms that primarily specialize in developing and launching generic drugs - is much sparser and stays that way over the span of our sample. Finally, when considering the common ownership links between brands firms, on the one hand, and generic firms, on the other, we find that brand firms have become more connected to generic firms over time. We discuss the potential antitrust implications of these findings.
Schlagwörter: 
Common ownership networks
pharmaceutical companies
competition
innovation
JEL: 
G23
K21
L11
L41
L65
Dokumentart: 
Working Paper

Datei(en):
Datei
Größe
1.7 MB





Publikationen in EconStor sind urheberrechtlich geschützt.